Intravenous immunoglobulin and atherosclerosis

Eiji Matsuura, Kazuko Kobayashi, Katsumi Inoue, Yehuda Shoenfeld

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Several inflammatory and immunological factors have been established as important contributors to atherogenesis. Among these, oxidized low-density lipoprotein (oxLDL) play a central role in the initiation and progression of atherosclerotic lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with β2-glycoprotein I (β2-GPI). Immunoglobulin (Ig)G autoantibodies against β2-GPI complexed with oxLDL are pro-atherogenic because they increase uptake of the complexes by macrophages. In contrast, IgM natural anti-oxLDL antibodies derived from atherosclerosis-prone apolipoprotein E (ApoE) deficient mice reduced incidence of atherosclerosis. Such anti-oxLDL antibodies have been found in humans, and the accumulating evidences seem to support the idea that anti-oxLDL antibodies have a protective role for atherogenesis. Intravenous immunoglobulins (IVIgs) contain natural anti-oxLDL antibodies and infusion of IVIg into ApoE-deficient mice has been reported to decrease atheerosclerosis. The anti-atherogenic property of IVIg may be derived from non-antigen-specific antibody binding to FCγ receptors, which blocks foam cell formation of macrophages. Several other possible mechanisms are also discussed.

Original languageEnglish
Pages (from-to)311-320
Number of pages10
JournalClinical Reviews in Allergy and Immunology
Volume29
Issue number3
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Intravenous Immunoglobulins
Atherosclerosis
Antibodies
Apolipoproteins E
Glycoproteins
Macrophages
Foam Cells
Immunologic Factors
oxidized low density lipoprotein
Autoantibodies
Immunoglobulin G
Incidence

Keywords

  • β-glycoprotein I (β-GPI)
  • Anti-oxLDL antibody
  • Atherosclerosis
  • Intravenous immunoglobulin (IVIg)
  • Oxidized low-density lipoprotien (oxLDL)

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Intravenous immunoglobulin and atherosclerosis. / Matsuura, Eiji; Kobayashi, Kazuko; Inoue, Katsumi; Shoenfeld, Yehuda.

In: Clinical Reviews in Allergy and Immunology, Vol. 29, No. 3, 12.2005, p. 311-320.

Research output: Contribution to journalArticle

Matsuura, Eiji ; Kobayashi, Kazuko ; Inoue, Katsumi ; Shoenfeld, Yehuda. / Intravenous immunoglobulin and atherosclerosis. In: Clinical Reviews in Allergy and Immunology. 2005 ; Vol. 29, No. 3. pp. 311-320.
@article{e044042a65204181bbaa3ed33799782b,
title = "Intravenous immunoglobulin and atherosclerosis",
abstract = "Several inflammatory and immunological factors have been established as important contributors to atherogenesis. Among these, oxidized low-density lipoprotein (oxLDL) play a central role in the initiation and progression of atherosclerotic lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with β2-glycoprotein I (β2-GPI). Immunoglobulin (Ig)G autoantibodies against β2-GPI complexed with oxLDL are pro-atherogenic because they increase uptake of the complexes by macrophages. In contrast, IgM natural anti-oxLDL antibodies derived from atherosclerosis-prone apolipoprotein E (ApoE) deficient mice reduced incidence of atherosclerosis. Such anti-oxLDL antibodies have been found in humans, and the accumulating evidences seem to support the idea that anti-oxLDL antibodies have a protective role for atherogenesis. Intravenous immunoglobulins (IVIgs) contain natural anti-oxLDL antibodies and infusion of IVIg into ApoE-deficient mice has been reported to decrease atheerosclerosis. The anti-atherogenic property of IVIg may be derived from non-antigen-specific antibody binding to FCγ receptors, which blocks foam cell formation of macrophages. Several other possible mechanisms are also discussed.",
keywords = "β-glycoprotein I (β-GPI), Anti-oxLDL antibody, Atherosclerosis, Intravenous immunoglobulin (IVIg), Oxidized low-density lipoprotien (oxLDL)",
author = "Eiji Matsuura and Kazuko Kobayashi and Katsumi Inoue and Yehuda Shoenfeld",
year = "2005",
month = "12",
doi = "10.1385/CRIAI:29:3:311",
language = "English",
volume = "29",
pages = "311--320",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Intravenous immunoglobulin and atherosclerosis

AU - Matsuura, Eiji

AU - Kobayashi, Kazuko

AU - Inoue, Katsumi

AU - Shoenfeld, Yehuda

PY - 2005/12

Y1 - 2005/12

N2 - Several inflammatory and immunological factors have been established as important contributors to atherogenesis. Among these, oxidized low-density lipoprotein (oxLDL) play a central role in the initiation and progression of atherosclerotic lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with β2-glycoprotein I (β2-GPI). Immunoglobulin (Ig)G autoantibodies against β2-GPI complexed with oxLDL are pro-atherogenic because they increase uptake of the complexes by macrophages. In contrast, IgM natural anti-oxLDL antibodies derived from atherosclerosis-prone apolipoprotein E (ApoE) deficient mice reduced incidence of atherosclerosis. Such anti-oxLDL antibodies have been found in humans, and the accumulating evidences seem to support the idea that anti-oxLDL antibodies have a protective role for atherogenesis. Intravenous immunoglobulins (IVIgs) contain natural anti-oxLDL antibodies and infusion of IVIg into ApoE-deficient mice has been reported to decrease atheerosclerosis. The anti-atherogenic property of IVIg may be derived from non-antigen-specific antibody binding to FCγ receptors, which blocks foam cell formation of macrophages. Several other possible mechanisms are also discussed.

AB - Several inflammatory and immunological factors have been established as important contributors to atherogenesis. Among these, oxidized low-density lipoprotein (oxLDL) play a central role in the initiation and progression of atherosclerotic lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with β2-glycoprotein I (β2-GPI). Immunoglobulin (Ig)G autoantibodies against β2-GPI complexed with oxLDL are pro-atherogenic because they increase uptake of the complexes by macrophages. In contrast, IgM natural anti-oxLDL antibodies derived from atherosclerosis-prone apolipoprotein E (ApoE) deficient mice reduced incidence of atherosclerosis. Such anti-oxLDL antibodies have been found in humans, and the accumulating evidences seem to support the idea that anti-oxLDL antibodies have a protective role for atherogenesis. Intravenous immunoglobulins (IVIgs) contain natural anti-oxLDL antibodies and infusion of IVIg into ApoE-deficient mice has been reported to decrease atheerosclerosis. The anti-atherogenic property of IVIg may be derived from non-antigen-specific antibody binding to FCγ receptors, which blocks foam cell formation of macrophages. Several other possible mechanisms are also discussed.

KW - β-glycoprotein I (β-GPI)

KW - Anti-oxLDL antibody

KW - Atherosclerosis

KW - Intravenous immunoglobulin (IVIg)

KW - Oxidized low-density lipoprotien (oxLDL)

UR - http://www.scopus.com/inward/record.url?scp=29944438053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944438053&partnerID=8YFLogxK

U2 - 10.1385/CRIAI:29:3:311

DO - 10.1385/CRIAI:29:3:311

M3 - Article

C2 - 16391407

AN - SCOPUS:29944438053

VL - 29

SP - 311

EP - 320

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 3

ER -